Sarepta Investors Race Against August 25 Deadline After ELEVIDYS Lawsuit Emerges
Big-name law firms sue Sarepta (Ticker: SRPT – NASDAQ, Biopharmaceuticals) after deadly trial setbacks
You can practically feel the urgency uptick as investors scramble to understand the fallout from today’s class action filing. If you traded Sarepta Therapeutics, Inc. (NASDAQ: SRPT)—a biopharmaceutical company—you’re right at the center of unfolding drama that could reshape everything you thought you knew about its pioneering gene therapy, ELEVIDYS.
This isn’t business as usual. Bragar Eagel & Squire, P.C. fired the starting gun today, reminding investors that a class action lawsuit has been filed against Sarepta, with lead plaintiff applications due by August 25, 2025. If you bought or otherwise acquired SRPT stock between June 22, 2023 and June 24, 2025, this notice applies directly to you.
What triggered this wave of litigation? The complaint charges Sarepta with repeatedly downplaying significant safety risks tied to ELEVIDYS, glossing over adverse events in trial protocols, and misleading investors about its growth prospects. That’s not all: on March 18, 2025, Sarepta disclosed a patient death from ELEVIDYS, triggering a massive 27% stock slide, with shares closing at $73.54.
The public saga worsened: on April 4, EU authorities demanded a review of that death; weeks later another patient passed away, prompting more trial suspensions and a 42% plunge; and on June 24, an FDA safety alert cited two deaths and launched an investigation. The reaction was swift—and brutal: an 8% further drop in the stock.
As of August 20, 2025, shares hovered around $20.58, reflecting the ongoing market shock and investor anxiety.
This is not a hidden bulletin—multiple firms, from Levi & Korsinsky to Pomerantz and Hagens Berman, are all lining up to represent aggrieved SRPT shareholders before that critical August 25 deadline.
From a human perspective, this is about more than numbers. It’s about trust, corporate responsibility, and the personal stakes investors carry when groundbreaking therapies collapse under scrutiny.
If you find yourself wondering, “Did I buy SRPT at the wrong time?”, you’re not alone—and right now, that decision could still bear tangible consequences. But if you're eligible, the window to step forward as a lead plaintiff is still wide open—until August 25, 2025.
